Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Lantern Pharma Inc

Healthcare US LTRN

3.565USD
-0.225(5.94%)

Last update at 2026-06-05T20:00:00Z

Day Range

3.503.78
LowHigh

52 Week Range

2.3811.99
LowHigh

Fundamentals

  • Previous Close 3.79
  • Market Cap66.49M
  • Volume242183
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-17.86296M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-1.6

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -14.25995M -12.36303M -5.90819M -2.42819M -1.72642M
Minority interest - - - - -
Net income -14.08714M -12.29510M -5.90819M -2.42819M -1.72642M
Selling general administrative 5.83M 5.02M 3.66M 1.48M 1.15M
Selling and marketing expenses - - - - -
Gross profit - - - - -
Reconciled depreciation 0.01M 0.00676M 0.00339M 0.00163M -0.00254M
Ebit -14.43275M -12.59151M -5.90819M -2.42819M -1.72387M
Ebitda -14.42267M -12.58475M -5.90480M -2.42656M -1.72642M
Depreciation and amortization 0.01M 0.00676M 0.00339M 0.00163M -0.00254M
Non operating income net other - - - - -
Operating income -14.43275M -12.59151M -5.90819M -2.42819M -1.72642M
Other operating expenses 14.43M 12.59M 5.91M 2.43M 1.73M
Interest expense 0.20M 0.22M 0.00000M 0.00000M 0.00000M
Tax provision - - - - -
Interest income 0.20M 0.07M - - -
Net interest income 0.20M 0.07M - - -
Extraordinary items - - - - -
Non recurring - - 2.24M - -
Other items - - - - -
Income tax expense -0.17281M -0.06793M - - 0.00254M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 14.43M 12.59M 5.91M 2.43M 1.73M
Cost of revenue - - - - -
Total other income expense net 0.17M 0.23M - - -
Discontinued operations - - - - -
Net income from continuing ops -14.25995M -12.36303M -5.90819M -2.42819M -1.72642M
Net income applicable to common shares -14.25995M -12.36303M -5.90819M -2.42819M -1.72642M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 43.65M 58.84M 73.95M 20.36M 1.43M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 1.18M 3.53M 1.99M 1.01M 0.00079M
Total liab 2.74M 2.80M 2.38M 0.66M 0.49M
Total stockholder equity 40.91M 56.04M 71.57M 19.70M 0.94M
Deferred long term liab - - - 0.10M 0.19M
Other current liab 2505.21M 2.75M 2.17M 0.55M 0.49M
Common stock 0.00107M 0.00109M 0.00111M 0.00062M 0.01M
Capital stock 0.00107M 0.00109M 0.00111M 0.00062M 0.03M
Retained earnings -55.24440M -39.28287M -25.02292M -12.65990M -6.75171M
Other liab - - - - -
Good will - - - - -
Other assets - 0.02M 1.02M 0.10M 0.19M
Cash 21.94M 37.20M 51.52M 19.23M 1.23M
Cash and equivalents - - - - -
Total current liabilities 2.68M 2.80M 2.33M 0.55M 0.49M
Current deferred revenue -2505.21100M - - - -
Net debt -21.70328M -37.14890M -51.31935M -19.12073M -1.23203M
Short term debt 0.17M 0.05M 0.15M - -
Short long term debt - - - - -
Short long term debt total 0.23M 0.05M 0.20M 0.11M -
Other stockholder equity 96.26M 95.69M 96.69M 32.36M 7.67M
Property plant equipment - 0.05M 0.22M 0.02M 0.00876M
Total current assets 43.34M 58.72M 72.72M 20.24M 1.23M
Long term investments - - - - -
Net tangible assets - 56.04M 71.57M 19.70M 0.94M
Short term investments 19.36M 17.99M 19.20M - -
Net receivables 0.86M 0.59M 0.18M - -
Long term debt - - - 0.11M -
Inventory - - - - -
Accounts payable 2.51M 2.75M 2.17M 0.54M 0.48M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -0.10746M -0.37139M -0.09269M - -
Additional paid in capital - - - - -
Common stock total equity - 0.00109M - 0.00062M 0.01M
Preferred stock total equity - - - - -
Retained earnings total equity - -39.28287M - -12.65990M -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.03M 0.02M 1.02M 0.10M 0.19M
Deferred long term asset charges - - - - -
Non current assets total 0.31M 0.11M 1.23M 0.12M 0.20M
Capital lease obligations 0.23M 0.05M 0.20M - -
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 0.21M -19.51509M -0.01614M -0.00572M 0.00534M
Change to liabilities 0.58M 1.62M 0.12M 0.37M 0.07M
Total cashflows from investing activities 0.18M -19.53059M -0.01614M -0.00572M 0.00534M
Net borrowings - - 0.11M 0.11M 0.11M
Total cash from financing activities -2.18250M 63.42M 23.66M 2.92M 0.54M
Change to operating activities -1.19222M -1.02213M -1.05623M -0.19179M 0.01M
Net income -14.25995M -12.36303M -5.90819M -2.42819M -1.72642M
Change in cash -14.78133M 33.30M 18.00M 0.79M -0.73118M
Begin period cash flow 52.52M 19.23M 1.23M 0.45M 1.18M
End period cash flow 37.74M 52.52M 19.23M 1.23M 0.45M
Total cash from operating activities -12.76749M -10.59154M -5.65162M -2.12792M -1.27152M
Issuance of capital stock 0.00000M 69.00M 26.25M 2.92M 0.00000M
Depreciation 0.01M 0.00676M 0.00339M 0.00163M -0.00254M
Other cashflows from investing activities - - -0.01614M - 0.00534M
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - - - - 0.19M
Sale purchase of stock -2.48229M - 26.30M 2.92M -
Other cashflows from financing activities 0.30M -5.58387M 23.83M -0.00572M 0.54M
Change to netincome 1.74M 1.16M 1.19M 0.12M 0.19M
Capital expenditures 0.03M 0.02M 0.02M 0.00572M 0.00572M
Change receivables - - - - -
Cash flows other operating -0.91870M - 0.14M - -
Exchange rate changes - - - - -
Cash and cash equivalents changes -14.77072M - 18.00M - -
Change in working capital -0.61186M 0.60M -0.93906M 0.18M 0.27M
Stock based compensation 1.19M 0.96M 1.19M 0.12M 0.19M
Other non cash items 0.91M 0.09M -19.88012M -0.76912M -
Free cash flow -12.79534M -10.60704M -5.66776M -2.13364M -1.27152M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
LTRN
Lantern Pharma Inc		 -0.225 5.94% 3.56 - - - 1.68 -1.5494
NVO
Novo Nordisk A/S		 -0.79 1.81% 42.96 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.6937 1.57% 43.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 5.09 1.15% 446.83 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 6.72 1.07% 635.45 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, and glioblastoma and other central nervous system cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma. The company develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and pediatric rare disease designation. In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Further, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. Lantern Pharma Inc. has a strategic AI-driven collaboration with Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications. The company was incorporated in 2013 and is headquartered in Dallas, Texas.

Lantern Pharma Inc

1920 McKinney Avenue, Dallas, TX, United States, 75201

Key Executives

Name Title Year Born
Mr. Panna Sharma PH.D. Pres, CEO & Director 1971
Mr. David R. Margrave CFO & Sec. 1961
Dr. Kishor Gopaldas Bhatia Ph.D. Chief Scientific Officer & Scientific Consultant 1955
Nicole Leber Investor Relations Associate, Fin. & Admin. Coordinator NA
Dr. Peter L. Nara D.V.M., M.S., Ph.D. Co-Founder & Advisor NA
Mr. Panna Sharma PH.D. President, CEO & Director 1971
Mr. David R. Margrave CFO & Secretary 1961
Nicole Leber Investor Relations Associate, Finance & Administrative Coordinator NA
Mr. Ernest Kitt B.S., M.S Head of Clinical Operations NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions